• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Xilio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    9/9/25 7:35:11 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XLO alert in real time by email
    0001840233false00018402332025-09-092025-09-09

    ​

    ​

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    WASHINGTON, D.C. 20549

    FORM 8-K

    ​

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    ​

    Date of report (Date of earliest event reported): September 9, 2025

    Xilio Therapeutics, Inc.

    (Exact Name of Registrant as Specified in Charter)

    ​

    Delaware

       

    001-40925

       

    85-1623397

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    ​

    ​

    ​

    828 Winter Street, Suite 300

    Waltham, Massachusetts

       

    02451

    (Address of Principal Executive Offices)

     

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: (857) 524-2466

    ​

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ​

    ☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ☐       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ​

    ☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ​

    ☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    ​

    ​

    ​

    ​

    Title of each class

       

    Trading symbol(s)

       

    Name of each exchange

    on which registered

    Common stock, par value $0.0001 per share

     

    XLO

     

    Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ​

    Emerging growth company  ☒

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    ​

    ​

    Item 8.01. Other Events.

    ​

    Initiation of Phase 2 Clinical Trial for Efarindodekin Alfa (XTX301) and Achievement of $17.5 Million Development Milestone

    ​

    On September 9, 2025, the Xilio Therapeutics, Inc. (the “Company”) issued a press release announcing the initiation of patient dosing in Phase 2 of an ongoing Phase 1/2 clinical trial evaluating efarindodekin alfa (XTX301), a tumor-activated IL-12, as a monotherapy in patients with certain advanced solid tumors, the achievement of a $17.5 million development milestone under the Company’s license agreement with Gilead Sciences, Inc. (“Gilead”) and updated data from the ongoing Phase 1 trial for efarindodekin alfa. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on, or accessible through, the websites referenced in the press release is not incorporated by reference into this Current Report on Form 8-K and should not be considered to be a part hereof.

    ​

    Updated Financial Guidance

    ​

    As of June 30, 2025, the Company had cash and cash equivalents of $121.6 million. Based on its current operating plans, the Company anticipates that its cash and cash equivalents as of June 30, 2025, together with the $17.5 million development milestone achieved under the license agreement with Gilead, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the first quarter of 2027. The Company expects to receive the $17.5 million development milestone payment by the fourth quarter of 2025.

    ​

    Cautionary Note Regarding Forward-Looking Statements

    ​

    This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the receipt of the development milestone payment and the Company’s anticipated cash runway. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this Current Report on Form 8-K are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form 8-K, including, without limitation, risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the United States or internationally. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the Company’s filings with the SEC, including the Company’s most recent Quarterly Report on Form 10-Q and any other filings that the Company has made or may make with the SEC in the future. Any forward-looking statements contained in this Current Report on Form 8-K represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.

    ​

    Item 9.01 Financial Statements and Exhibits.

    ​

    (d) Exhibits.

    ​

    ​

    ​

    ​

    Exhibit No.

    ​

    Description

    99.1

    ​

    Press release issued by Xilio Therapeutics, Inc. on September 9, 2025

    104

    ​

    Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    XILIO THERAPEUTICS, INC.

     

     

     

    Date: September 9, 2025

    By:

    /s/ Caroline Hensley

     

     

    Caroline Hensley

     

     

    Chief Legal Officer

    ​

    ​

    ​

    ​

    ​

    ​

    Get the next $XLO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XLO

    DatePrice TargetRatingAnalyst
    8/6/2025$2.00Outperform
    Leerink Partners
    12/21/2022$7.00Buy
    Chardan Capital Markets
    1/10/2022$36.00Buy
    HC Wainwright & Co.
    11/16/2021$40.00Buy
    Guggenheim
    11/16/2021$31.00Outperform
    Raymond James
    11/16/2021Outperform
    Cowen & Co.
    11/16/2021$32.00Overweight
    Morgan Stanley
    More analyst ratings

    $XLO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

    Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the initiation of patient dosing in Phase 2 of an ongoing Phase 1/2 clinical trial evaluating efarindodekin alfa (XTX301), a tumor-activated IL-12, as a monotherapy in patients with certain advanced solid tumors. In addition, today X

    9/9/25 7:30:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

    Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy On track with plans to nominate first development candidates for wholly owned masked T cell engager programs in second half of 2025 $121.6 million in cash and cash equivalents as of June 30, 2025, with anticipated cash runway through end of third quarter of 2026 WALTHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-o

    8/14/25 7:30:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

    CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases. "Da

    8/4/25 8:03:00 AM ET
    $CPRX
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Xilio Therapeutics with a new price target

    Leerink Partners initiated coverage of Xilio Therapeutics with a rating of Outperform and set a new price target of $2.00

    8/6/25 7:25:30 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Xilio Therapeutics with a new price target

    Chardan Capital Markets initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $7.00

    12/21/22 7:57:28 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Xilio Therapeutics with a new price target

    HC Wainwright & Co. initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $36.00

    1/10/22 6:12:33 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:57:19 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:56:47 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by PRESIDENT AND CEO Russo Rene

    4/A - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:55:49 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:57:19 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:56:47 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gilead Sciences, Inc. bought $1,830,377 worth of shares (1,759,978 units at $1.04), increasing direct ownership by 24% to 9,105,451 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    12/19/24 4:19:34 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    SEC Filings

    View All

    Xilio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

    9/9/25 7:35:11 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

    8/28/25 4:05:23 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Xilio Therapeutics Inc.

    SCHEDULE 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    8/14/25 4:42:16 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Leadership Updates

    Live Leadership Updates

    View All

    Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

    CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases. "Da

    8/4/25 8:03:00 AM ET
    $CPRX
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

    WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company's board of directors. "Tunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board," said Paul Clancy, chair of the board of dire

    6/10/25 4:30:00 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

    Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T cell engager programs in novel ATACR and SEECR formats for PSMA, CLDN18.2 and STEAP1 Announced collaboration with AbbVie in the first quarter of 2025 to develop novel tumor-activated, antibody-based immunotherapies, including masked T cell engagers WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipe

    3/11/25 7:30:58 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Financials

    Live finance-specific insights

    View All

    Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

    Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended anticipated cash runway into the first quarter of 2026 Company to host investor conference call and webcast today at 8:30 am ET WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen (PSMA), claudi

    2/12/25 7:35:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

    Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging X

    2/12/25 7:33:00 AM ET
    $ABBV
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

    Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am ESTNORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's p

    2/12/25 7:30:00 AM ET
    $ABBV
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 5:44:28 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 4:30:23 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/12/24 4:50:36 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care